Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloRx for Chronic Kidney Disease
NCT05018845Phase 1Terminated
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Nov 2021
- Primary completion
- Nov 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AlloRx in chronic kidney disease (CKD), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 4 years. Started Nov 2021; status: terminated.
02
Drugs
AlloRx
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05018845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018845.